461 related articles for article (PubMed ID: 21834756)
21. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
23. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
Rosa R; Damiano V; Nappi L; Formisano L; Massari F; Scarpa A; Martignoni G; Bianco R; Tortora G
Br J Cancer; 2013 Aug; 109(3):686-93. PubMed ID: 23839492
[TBL] [Abstract][Full Text] [Related]
24. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
Beljanski V; Lewis CS; Smith CD
Cancer Biol Ther; 2011 Mar; 11(5):524-34. PubMed ID: 21258214
[TBL] [Abstract][Full Text] [Related]
26. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
[TBL] [Abstract][Full Text] [Related]
27. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.
Zhu AX; Duda DG; Sahani DV; Jain RK
Cancer J; 2009; 15(4):263-8. PubMed ID: 19672141
[TBL] [Abstract][Full Text] [Related]
28. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
[TBL] [Abstract][Full Text] [Related]
29. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
[TBL] [Abstract][Full Text] [Related]
30. Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma
Tsai JJ; Hsu FT; Pan PJ; Chen CW; Kuo YC
Anticancer Res; 2018 Apr; 38(4):2119-2125. PubMed ID: 29599330
[TBL] [Abstract][Full Text] [Related]
31. Molecular mechanisms of sorafenib action in liver cancer cells.
Cervello M; Bachvarov D; Lampiasi N; Cusimano A; Azzolina A; McCubrey JA; Montalto G
Cell Cycle; 2012 Aug; 11(15):2843-55. PubMed ID: 22801548
[TBL] [Abstract][Full Text] [Related]
32. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
Hu S; Niu H; Minkin P; Orwick S; Shimada A; Inaba H; Dahl GV; Rubnitz J; Baker SD
Mol Cancer Ther; 2008 May; 7(5):1110-20. PubMed ID: 18483300
[TBL] [Abstract][Full Text] [Related]
33. PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma?
Oseini AM; Roberts LR
Expert Opin Ther Targets; 2009 Apr; 13(4):443-54. PubMed ID: 19335066
[TBL] [Abstract][Full Text] [Related]
34. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma.
Nagel C; Armeanu-Ebinger S; Dewerth A; Warmann SW; Fuchs J
Exp Cell Res; 2015 Feb; 331(1):97-104. PubMed ID: 25447203
[TBL] [Abstract][Full Text] [Related]
36. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy.
Wu JM; Sheng H; Saxena R; Skill NJ; Bhat-Nakshatri P; Yu M; Nakshatri H; Maluccio MA
Cancer Lett; 2009 Jun; 278(2):145-155. PubMed ID: 19303700
[TBL] [Abstract][Full Text] [Related]
37. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
Martin B; Edeline J; Patard JJ; Oger E; Jouan F; Boulanger G; Zerrouki S; Vigneau C; Rioux-Leclercq N
J Cancer Res Clin Oncol; 2012 Jun; 138(6):907-16. PubMed ID: 22322364
[TBL] [Abstract][Full Text] [Related]
38. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
39. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
Stein MN; Flaherty KT
Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
[No Abstract] [Full Text] [Related]
40. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]